Advertisement

New methods for probing the disposition of nicotine in humans

  • J. Wahren
  • J. Gabrielsson
  • M. Curvall
  • E. Kazemi Vala

Abstract

For many centuries nicotine has been consumed by humans in different forms of tobacco. More recently nicotine itself has become available as a pharmaceutical agent in the form of nicotine-containing chewing gum or nicotine preparations for transdermal absorption. The importance of nicotine in human physiology is related to its pleasurable effects as well as to its possible role in tobacco-related disorders. It may be assumed that, as with most pharmacological agents, there is a relationship between plasma concentration of nicotine and its pharmacological effects. It follows that the factors which determine the disposal of nicotine may influence the effects of nicotine during tobacco use as well as its effects when nicotine is used as an adjuvant to smoking cessation. A detailed understanding of whole body and regional disposal of nicotine is of interest with regard to the basic physiology and pharmacology of nicotine. It is noteworthy that literature is almost totally, devoid of information concerning the influence of disease on the pharmacokinetics of nicotine. Thus, data with regard to the influence of, e.g. liver disease or renal disease on nicotine disposal are not available but may well be of clinical interest.

Keywords

Positron Emission Tomography Nuclear Magnetic Resonance Nicotine Concentration Renal Uptake High Infusion Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Benowitz, N.L., Porchet, H., Sheiner, L. et al(1990) Pharmacokinetics, metabolism, and pharmacodynamics of nicotine, in Nicotine Psychopharmacology: Molecular, Cellular and Behavioral Aspects, (eds S. Wonnacott, M.A.H Russell and LP. Stolerman ), Oxford University Press, Oxford, pp. 112–57.Google Scholar
  2. Björkman, O., Gunnarsson, R., Felig, P. et al(1989) Splanchnic and renal exchange of infused fructose in insulin-deficient type I diabetic patients and healthy controls. J. Clin. Invest., 83, 52–9.PubMedCrossRefGoogle Scholar
  3. Caldwell, W.S., Greene, J.M., Byrd, G.D. et al(1992) Characterization of the glucuronide conjugate of cotinine: a previously unidentified major metabolite of nicotine in smokers’ urine. Chem. Res. Toxicol, 5, 280–5PubMedCrossRefGoogle Scholar
  4. Curvall, M., Kazemi Vala, E. and Enzell, C.R. (1982). Simultaneous determination of nicotine and cotinine in plasma using capillary column gas chromatography with nitrogen-sensitive detection. J. Chromatog. Biomed. Appl, 232, 283–93.CrossRefGoogle Scholar
  5. Curvall, M., Kazemi Vala, E., Enzell, C.R. et al(1990) Simulation and evaluation of nicotine intake during passive smoking: Cotinine measurements in body fluids of nonsmokers given intravenous infusions of nicotine. Clin. Pharmacol Ther., 47, 42–9.PubMedCrossRefGoogle Scholar
  6. Dewey, S.L., Volkow, N.D., Logan, J. et al(1990) Age-related decreases in muscarinic cholinergic receptor binding in the human brain measured with positron emission tomography (PET). J. Neurosci. Res., 27, 569–75.PubMedCrossRefGoogle Scholar
  7. Frackowiak, R.S.J., Pozzilli, C., Legg, N.J. et al(1981) Regional cerebral oxygen supply and reutilization in dementia. A clinical and physiological study in oxygen-15 and positron emission tomography. Brain, 104, 753–78.PubMedCrossRefGoogle Scholar
  8. Frahm, J., Merboldt, K.-D. and Hänicke, W. (1993) Functional MRI of human brain activation at high spatial resolution. Magn. Res. Med., 29, 139–44.CrossRefGoogle Scholar
  9. Hofstetter, A., Schutz, Y., Jequier, E. et al(1986) Increased 24-hour energy expenditure in cigarette smokers. New Engl J. Med., 314, 79–82.PubMedCrossRefGoogle Scholar
  10. Kyerematen, G.A. and Vesell, E.S. (1991). Metabolism of nicotine. Drug Metab. Rev., 23, 3–41.PubMedCrossRefGoogle Scholar
  11. Långström, B., Antoni, G., Halldin, C. et al(1982) The synthesis of some 11C-labelled alkaloids. Chemica Scripta, 20, 46–8.Google Scholar
  12. Nordberg, A., Nilsson-Håkansson, L., Adem, A. et al(1989) The role of the nicotinic receptors in the pathophysiology of Alzheimer’s disease. Prog. Brain Res., 79, 353–62.PubMedCrossRefGoogle Scholar
  13. Nordberg, A., Hartvig, P., Lilja, A. et al(1991) Nicotine receptors in the CNS as visualized by positron emission tomography, in Cholinergic Basis for Alzheimer Therapy, (eds R. Becker and E. Giacobini ), Birkhâuser, Basel, pp. 107–15.Google Scholar
  14. Nybäck, H., Nordberg, A., Långström, B. et al(1989) Attempts to visualize nicotinic receptors in the brain of monkey and man by positrion emission tomography. Prog. Brain Res., 79, 313–9.PubMedCrossRefGoogle Scholar
  15. Parviainen, M.T., Puhakainen, E.V., Laatikainen, R. et al(1990) Nicotine metabolites in the urine of smokers. J. Chromatog., 525, 193–202.CrossRefGoogle Scholar
  16. Rosenberg, J., Benowitz, N.L., Peyton, J. et al(1980) Disposition kinetics and effects of intravenous nicotine. Clin. Pharmacol Therap., 28, 517–22.CrossRefGoogle Scholar
  17. Schievelbein, H. (1982). Nicotine, resorption and fate. Pharmac. Ther., 18, 233–48.CrossRefGoogle Scholar
  18. Svensson, C.K. (1987). Clinical pharmacokinetics of nicotine. Clin. Pharmacokin., 12, 30–40.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1993

Authors and Affiliations

  • J. Wahren
  • J. Gabrielsson
  • M. Curvall
  • E. Kazemi Vala

There are no affiliations available

Personalised recommendations